Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;39(1):13-26.
doi: 10.1007/s10719-021-10002-2. Epub 2021 May 26.

A critical role for GM1 ganglioside in the pathophysiology and potential treatment of Parkinson's disease

J S Schneider  1
Affiliations
Review

A critical role for GM1 ganglioside in the pathophysiology and potential treatment of Parkinson's disease

J S Schneider. Glycoconj J. 2022 Feb.

Abstract

Parkinson's disease (PD) is slowly progressing neurodegenerative disorder that affects millions of patients worldwide. While effective symptomatic therapies for PD exist, there is no currently available disease modifying agent to slow or stop the progression of the disease. Many years of research from various laboratories around the world have provided evidence in favor of the potential ability of GM1 ganglioside to be a disease modifying agent for PD. In this paper, information supporting the use of GM1 as a disease modifying therapeutic for PD is reviewed along with information concerning the role that deficiencies in GM1 ganglioside (and potentially other important brain gangliosides) may play in the pathogenesis of PD.

Keywords: GM1; Ganglioside; Neuroprotection; Parkinson’s disease.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Marras, C., Tanner, C.M.: The epidemiology of Parkinson's disease. In: Watts, R.L., Koller, W.C. (eds.) Movememnt Disorders Neurological Principles and Pratice, pp. 177–196. McGraw-Hill, New York (2002)
    1. Dorsey, E.R., Constantinescu, R., Thompson, J.P., Biglan, K.M., Holloway, R.G., Kieburtz, K., Marshall, F.J., Ravina, B.M., Schifitto, G., Siderowf, A., Tanner, C.M.: Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 68(5), 384–386 (2007). https://doi.org/10.1212/01.wnl.0000247740.47667.03 - DOI - PubMed
    1. Schneider, J.S., Gollomp, S.M., Sendek, S., Colcher, A., Cambi, F., Du, W.: A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients. J. Neurol. Sci. 324(1–2), 140–148 (2013). https://doi.org/10.1016/j.jns.2012.10.024 - DOI - PubMed
    1. Agnati, L.F., Fuxe, K., Calza, L., Benfenati, F., Cavicchioli, L., Toffano, G., Goldstein, M.: Gangliosides increase the survival of lesioned nigral dopamine neurons and favour the recovery of dopaminergic synaptic function in striatum of rats by collateral sprouting. Acta Physiol. Scand. 119(4), 347–363 (1983). https://doi.org/10.1111/j.1748-1716.1983.tb07363.x - DOI - PubMed
    1. Toffano, G., Savoini, G., Moroni, F., Lombardi, G., Calza, L., Agnati, L.F.: GM1 ganglioside stimulates the regeneration of dopaminergic neurons in the central nervous system. Brain Res. 261(1), 163–166 (1983) - DOI

Publication types

LinkOut - more resources